PPL is developing a research pipeline of Antp-based drug candidates and
is evaluating their function and potential as new therapeutic agents
for a variety of non-oncology indications.
PPL currently has nine biotech professionals acting as consultants. They
are led by Dr. Bruce Littman as Chief Executive Officer and President,
and Dr. Frank Marcoux as Chief Scientific Officer. They report to the
Board of Directors of PPL which is headed by Dr. Declan Doogan. Drs.
Littman, Marcoux and Doogan have over 60 years of combined experience
in the financing and development of new drugs and have been associated
with major pharmaceutical companies in executive positions. PPL plans
on streamlining its drug development process through contract research
organizations. This strategy offers the benefit of fast delivery, a
higher level of efficiency and lowered costs associated with drug
The following are the backgrounds of the new management and Board
Gregory Bailey M.D. is a co-founder of Ascent Healthcare Solutions, the number one
re-processor of used surgical equipment; VirnetX Inc., an internet
security company (VHC: AMEX); and Duramedic Inc., a medical products
company. He is a former financier and director of Medivation Inc.
(MDVN: NASDAQ) from 2005 to 2012.
Declan Doogan M.D. was the previous CEO and Head of R&D at Amarin Inc. (AMRN:NASDAQ) and
the former Head of Worldwide Drug Development at Pfizer Inc. He has
held Visiting Professorships at Harvard School of Public Health,
Glasgow UniversityMedical School and Kitasato University (Tokyo). He
sits on the boards of Pulmonary Vascular Research Institute UK, Sosei
(Japan Biotech), Trojantec (UK, oncology) and Spinifex (Melbourne). He
continues to provide medical advice to Amarin Inc.
Jim Mellon: Jim holds directorships in a number of publicly quoted companies, many
of which are in the biopharma sector including Miraculins, Plethora
Solutions, and the Summit Corporation. He is also chairman of AIM
listed Port Erin Biopharma Investments, a fund specialising in
biopharma investments and is the author of the best-selling book
"Cracking the Code" which charts the developments within the biotech
industry. Jim's other listed company directorships include chairman of
Manx Financial Group and Speymill, co-chairman of both Regent Pacific
Group and West African Mining Corporation, and a board member of
Brazilian Gold Corporation, Charlemagne Capital and Condor Resources.